104 related articles for article (PubMed ID: 19860843)
1. Role of syndecan-1 (CD138) in cell survival of human urothelial carcinoma.
Shimada K; Nakamura M; De Velasco MA; Tanaka M; Ouji Y; Miyake M; Fujimoto K; Hirao K; Konishi N
Cancer Sci; 2010 Jan; 101(1):155-60. PubMed ID: 19860843
[TBL] [Abstract][Full Text] [Related]
2. Syndecan-1, a new target molecule involved in progression of androgen-independent prostate cancer.
Shimada K; Nakamura M; De Velasco MA; Tanaka M; Ouji Y; Konishi N
Cancer Sci; 2009 Jul; 100(7):1248-54. PubMed ID: 19432893
[TBL] [Abstract][Full Text] [Related]
3. Inducing cell proliferation inhibition, apoptosis, and motility reduction by silencing long noncoding ribonucleic acid metastasis-associated lung adenocarcinoma transcript 1 in urothelial carcinoma of the bladder.
Han Y; Liu Y; Nie L; Gui Y; Cai Z
Urology; 2013 Jan; 81(1):209.e1-7. PubMed ID: 23153939
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive squamous lesions in the urinary bladder: a clinicopathologic analysis of 29 cases.
Guo CC; Fine SW; Epstein JI
Am J Surg Pathol; 2006 Jul; 30(7):883-91. PubMed ID: 16819332
[TBL] [Abstract][Full Text] [Related]
5. Motility-related protein 1 (MRP-1/CD9) expression in urothelial bladder carcinoma and its relation to tumor recurrence and progression.
Mhawech P; Herrmann F; Coassin M; Guillou L; Iselin CE
Cancer; 2003 Oct; 98(8):1649-57. PubMed ID: 14534881
[TBL] [Abstract][Full Text] [Related]
6. Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression.
Nikolova V; Koo CY; Ibrahim SA; Wang Z; Spillmann D; Dreier R; Kelsch R; Fischgräbe J; Smollich M; Rossi LH; Sibrowski W; Wülfing P; Kiesel L; Yip GW; Götte M
Carcinogenesis; 2009 Mar; 30(3):397-407. PubMed ID: 19126645
[TBL] [Abstract][Full Text] [Related]
7. Effect of small interfering RNA targeting survivin gene on biological behaviour of bladder cancer.
Hou JQ; He J; Wang XL; Wen DG; Chen ZX
Chin Med J (Engl); 2006 Oct; 119(20):1734-9. PubMed ID: 17097022
[TBL] [Abstract][Full Text] [Related]
8. c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations.
Korkolopoulou P; Goudopoulou A; Voutsinas G; Thomas-Tsagli E; Kapralos P; Patsouris E; Saetta AA
Urology; 2004 Jun; 63(6):1198-204. PubMed ID: 15183989
[TBL] [Abstract][Full Text] [Related]
9. siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth.
Ning S; Fuessel S; Kotzsch M; Kraemer K; Kappler M; Schmidt U; Taubert H; Wirth MP; Meye A
Int J Oncol; 2004 Oct; 25(4):1065-71. PubMed ID: 15375557
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma.
Theodoropoulos VE; Lazaris AC; Kastriotis I; Spiliadi C; Theodoropoulos GE; Tsoukala V; Patsouris E; Sofras F
BJU Int; 2005 Feb; 95(3):425-31. PubMed ID: 15679808
[TBL] [Abstract][Full Text] [Related]
11. Association of syndecan-1 with tumor grade and histology in primary invasive cervical carcinoma.
Rintala M; Inki P; Klemi P; Jalkanen M; Grénman S
Gynecol Oncol; 1999 Dec; 75(3):372-8. PubMed ID: 10600292
[TBL] [Abstract][Full Text] [Related]
12. Expression of the human mismatch repair gene hMSH2: a potential marker for urothelial malignancy.
Leach FS; Hsieh JT; Molberg K; Saboorian MH; McConnell JD; Sagalowsky AI
Cancer; 2000 May; 88(10):2333-41. PubMed ID: 10820356
[TBL] [Abstract][Full Text] [Related]
13. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
[TBL] [Abstract][Full Text] [Related]
14. The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer.
Divrik RT; Sahin A; Altok M; Unlü N; Zorlu F
J Urol; 2007 Sep; 178(3 Pt 1):802-6; discussion 806. PubMed ID: 17632171
[TBL] [Abstract][Full Text] [Related]
15. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.
Inman BA; Sebo TJ; Frigola X; Dong H; Bergstralh EJ; Frank I; Fradet Y; Lacombe L; Kwon ED
Cancer; 2007 Apr; 109(8):1499-505. PubMed ID: 17340590
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of laminin-5 gamma2 chain and its prognostic significance in urothelial carcinoma of urinary bladder: association with expression of cyclooxygenase 2, epidermal growth factor receptor [corrected] and human epidermal growth factor receptor [corrected] 2.
Kiyoshima K; Oda Y; Kinukawa N; Naito S; Tsuneyoshi M
Hum Pathol; 2005 May; 36(5):522-30. PubMed ID: 15948119
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder.
Wild PJ; Herr A; Wissmann C; Stoehr R; Rosenthal A; Zaak D; Simon R; Knuechel R; Pilarsky C; Hartmann A
Clin Cancer Res; 2005 Jun; 11(12):4415-29. PubMed ID: 15958626
[TBL] [Abstract][Full Text] [Related]
19. Induced expression of syndecan-1 in the stroma of head and neck squamous cell carcinoma.
Mukunyadzi P; Liu K; Hanna EY; Suen JY; Fan CY
Mod Pathol; 2003 Aug; 16(8):796-801. PubMed ID: 12920224
[TBL] [Abstract][Full Text] [Related]
20. Rhabdomyosarcoma of the urinary bladder in adults: predilection for alveolar morphology with anaplasia and significant morphologic overlap with small cell carcinoma.
Paner GP; McKenney JK; Epstein JI; Amin MB
Am J Surg Pathol; 2008 Jul; 32(7):1022-8. PubMed ID: 18469707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
